MUGNAINI CLAUDIA

Claudia
Mugnaini
Professore Associato

Presentation

I am an Associate Professor of Medicinal Chemistry and my research is focused on the design and synthesis of small heterocyclic molecules endowed with a potential pharmacological application. 

Main areas of interest:

  • new selective ligands for the CB2 receptor
  • allosteric modulators of GABAB receptor
  • new antibiotic adjuvants active on EXCAPE pathogens 
  • multi-target-directed ligands for the treatment of neurodegenerative disorders 

 

Office hours

  • Wednesday from 14:00 to 16:00
    Place: Studio del docente - Polo Scientifico Universitario di San Miniato

Contacts

0577232434 [int.2434],0577234312 [int.4312] (Lab 10128)

Curriculum Vitae

Teaching activities

Completion accademic year: 2025/2026

Completion accademic year: 2024/2025

Completion accademic year: 2023/2024

Completion accademic year: 2022/2023

Research

Ultime pubblicazioni:

  • Maramai, S., Mugnaini, C., Paolino, M., Schiano Moriello, A., De Petrocellis, L., Corelli, F., et al. (2025). Indole-2-Carboxamide as an Effective Scaffold for the Design of New TRPV1 Agonists. MOLECULES, 30(3) [10.3390/molecules30030721]. - view more
  • Poggialini, F., Governa, P., Vagaggini, C., Maramai, S., Lamponi, S., Mugnaini, C., et al. (2025). Light-mediated activation/deactivation control and in vitro ADME-Tox profiling of a donepezil-like Dual AChE/MAO-B Inhibitor. EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES, 209 [10.1016/j.ejps.2025.107066]. - view more
  • Mugnaini, C., Brizzi, A., Paolino, M., Scarselli, E., Castelli, R., de Candia, M., et al. (2024). Novel Dual-Acting Hybrids Targeting Type-2 Cannabinoid Receptors and Cholinesterase Activity Show Neuroprotective Effects In Vitro and Amelioration of Cognitive Impairment In Vivo. ACS CHEMICAL NEUROSCIENCE, 15(5), 955-971 [10.1021/acschemneuro.3c00656]. - view more
  • Avigliano, M., Francesco, D.D., Brizzi, A., Paolino, M., Corelli, F., Mugnaini, C. (2023). Synthesis of some novel 1-aryl-1H-1,2,3-triazole-4-carboxamides and ethyl 1-aryl-5-(1,2,3-triazol-1-yl)-1H-pyrazole-4-carboxylates. ARKIVOC, 2023(7), 1-11 [10.24820/ark.5550190.p011.966]. - view more
  • Borgonetti, V., Mugnaini, C., Corelli, F., Galeotti, N. (2023). The Selective CB2 Agonist COR167 Reduced Symptoms in a Mice Model of Trauma-Induced Peripheral Neuropathy through HDAC-1 Inhibition. BIOMEDICINES, 11(6) [10.3390/biomedicines11061546]. - view more